Following the earlier introduction of Onbrez® (indacaterol) and Seebri® (glycopyrronium bromide), Novartis have combined the long-acting beta2-agonist (LABA) and long-acting muscarinic receptor antagonist (LAMA) in Ultibro® Breezhaler® (indacaterol/glycopyrronium) 110/50, a once daily treatment for moderate to severe congestive obstructive pulmonary disease (COPD). The dual mode of action of indacaterol and glycopyrronium to target different pathways for optimal bronchodilation, is expected to produce additive efficacy at lower doses than using two single agents alone.

With Ultibro® integrated into the COPD stepwise management approach, physicians have another choice to consider for further symptom relief and prevention of exacerbation. Furthermore, these combination products may delay the introduction of inhaled corticosteroid therapy in some mild to moderately severe COPD patients, avoiding the introduction of other risks such as pneumonia and oropharyngeal adverse effects.

Ultibro® Breezhaler® 100/50 is available on authority prescription under the Pharmaceutical Benefits Scheme for COPD patients who have stabilised with the combination of a LABA and a LAMA.

References:

  1. Abramson M, Brown J, Crockett AJ, Dabscheck AJ, Frith PA Geoge J, etal. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2014. Version 2.39. Lung Foundation Australia: 2014.
  2. Lung Foundation Australia, Stepwise Management of Stable COPD. Milton QLD: Lung Foundation Australia; 2014.
  3. Pharmaceutical Benefits Advisory Committee. Public Summary Document: INDACATEROL WITH GLYCOPYRRONIUM (FDC), indacaterol 110 microgram + glycopyrronium 50 microgram, inhalation: powder for, 30 capsules, Ultibro® Breezhaler® 110/50, Novartis Pharmaceuticals Australia Pty Ltd– July 2014. Canberra: Australian Government Department of Health and Ageing; 2014.
  4. Ultibro® Breezhaler® 110/50 (indacaterol maleate/ glycopyrronium bromide) Australian approved consumer medicines information. North Ryde: Novartis Pharmaceuticals Australia Pty Limited. Approved 21 March 2014.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates